A5034841206- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- vaccines and immunoinformatics approaches
- Viral gastroenteritis research and epidemiology
- SARS-CoV-2 detection and testing
- Vaccine Coverage and Hesitancy
- Bacillus and Francisella bacterial research
- Animal Virus Infections Studies
- Viral Infections and Immunology Research
- Biomarkers in Disease Mechanisms
- Monoclonal and Polyclonal Antibodies Research
- Immunotherapy and Immune Responses
- Adipokines, Inflammation, and Metabolic Diseases
- Cybercrime and Law Enforcement Studies
- Dialysis and Renal Disease Management
- Intramuscular injections and effects
- Law, AI, and Intellectual Property
- Heparin-Induced Thrombocytopenia and Thrombosis
- Gambling Behavior and Treatments
- Legal Education and Practice Innovations
- Crime, Illicit Activities, and Governance
- Judicial and Constitutional Studies
- Artificial Intelligence in Law
- Peptidase Inhibition and Analysis
- Spam and Phishing Detection
Translational Health Science and Technology Institute
2021-2024
Institute of Genomics and Integrative Biology
2024
Institute of Management Technology
2023
King George's Medical University
2011
Rapid spread of the omicron SARS-CoV-2 variant despite extensive vaccination suggests immune escape. The neutralising ability different vaccines alone or with natural infection against is not well-known.In this cross-sectional study, we tested vaccine and induced antibodies to neutralise in a live virus neutralisation assay four groups individuals: (i) ChAdOx1 nCoV-19 vaccination, (ii) plus prior infection, (iii) inactivated (BBV152), (iv) BBV152 infection. Primary outcome was fold-change...
Optimum formulation of Biological-E's protein subunit CORBEVAX™ vaccine was selected in phase-1 and -2 studies found to be safe immunogenic healthy adult population. This is a phase-3 prospective, single-blinded, randomized, active controlled study conducted at 18 sites across India 18–80 year-old subjects. has two groups; (i) immunogenicity-group, participants randomized either (n = 319) or COVISHIELD™ arms 320). (ii) Safety-group containing single arm 1500) randomization not applicable....
BackgroundAccurate quantitation of immune markers is crucial for ensuring reliable assessment vaccine efficacy against infectious diseases. This study was designed to confirm standardised performance SARS-CoV-2 assays used evaluate COVID-19 candidates at the initial seven laboratories (in North America, Europe, and Asia) Coalition Epidemic Preparedness Innovations (CEPI) Centralized Laboratory Network (CLN).MethodsThree ELISAs (pre-spike protein, receptor binding domain, nucleocapsid), a...
The Omicron variant of SARS-CoV-2 is capable infecting unvaccinated, vaccinated and previously-infected individuals due to its ability evade neutralization by antibodies. With multiple sub-lineages emerging in the last 12 months, there inadequate information on quantitative antibody response generated upon natural infection with whether these antibodies offer cross-protection against other variant. In this study, we characterized growth kinetics Kappa, Delta variants Calu-3 cells. Relatively...
A recently emerged sub-lineage of Omicron, BA.5, together with BA.4, caused a fifth wave coronavirus disease (COVID-19) in South Africa and subsequently as predominant strain globally due to its high transmissibility. The lethality BA.5 infection has not been studied an acute hACE2 transgenic (hACE2.Tg) mouse model. Here, we investigated tissue-tropism immuno-pathology induced by hACE2.Tg mice. Our data show that intranasal mice resulted attenuated pulmonary pathology diminished...
Abstract Many adults in India have received at least one dose of COVID-19 vaccine with or without a prior history SARS-CoV-2 infection. However, there is limited information on the effect immunity antibody response upon vaccination India. As immunization individuals continues, we aimed to assess whether pre-existing antibodies are further boosted by single BBV152, an inactivated vaccine, and, if these can neutralize Delta and Omicron variants. Here show that natural infection during second...
Although efficacious vaccines have significantly reduced the morbidity and mortality of COVID-19, there remains an unmet medical need for treatment options, which monoclonal antibodies (mAbs) can potentially fill. This is exacerbated by emergence spread SARS-CoV-2 variants concern (VOCs) that shown some resistance to vaccine responses. Here we report isolation five neutralizing mAbs from Indian convalescent donor, out two (THSC20.HVTR04 THSC20.HVTR26) showed potent neutralization VOCs at...
The emergence of new variants SARS-CoV-2 necessitates unremitting efforts to discover novel therapeutic monoclonal antibodies (mAbs). Here, we report an extremely potent mAb named P4A2 that can neutralize all the circulating concern (VOCs) with high efficiency, including highly transmissible Omicron. crystal structure Fab:RBD complex revealed residues RBD interact are a part ACE2-receptor-binding motif and not mutated in any VOCs. pan coronavirus pseudotyped neutralization assay confirmed is...
Abstract Background Rapid expansion of the omicron SARS-CoV-2 variant concern despite extensive vaccine coverage might be related to decreased neutralising ability induced antibodies. The different vaccines with or without natural infection against is however not well known. Methods We tested and antibodies neutralise in a live virus neutralisation assay. Four groups individuals were included: (i) complete vaccination ChAdOx1 nCoV-19 (n=20), (ii) plus prior during delta driven surge (iii)...
Background: Optimum formulation of Biological Es CORBEVAX vaccine that contains protein sub unit Receptor Binding Domain (RBD) from the spike SARS-COV-2 formulated with aluminum hydroxide (Al3+) and CpG1018 as adjuvants was selected in phase-1 2 studies proven to be safe, well tolerated immunogenic healthy adult population. In current study, additional data generated determine superiority over COVISHIELD safety larger older Methods: This is a phase III prospective, single blinded,...
ABSTRACT Background We present the data from an open-label study involved in selection of optimum formulation RBD-based protein sub-unit COVID-19 vaccine. Methods The randomized Phase-1/2 trial followed by a Phase-2 was carried out to assess safety and immunogenicity different vaccine (Corbevax) select for phase 3 study. Healthy adults without history Covid-19 vaccination or SARS-CoV-2 infection, were enrolled. Findings Low incidence adverse events reported post-vaccination Corbevax...
Let’s start with understanding the meaning of above quotation which is, that to provide justice properly needy person few things should always be kept in mind legal system (lawyers, justice, law officers) check possible ways person, no one away from justice. For that, many lawyers free aid people who cannot afford court and lawyer’s fees. Now let us understand basic terms topic by one. Let's term investigation, it is a type examination done find some facts about situation may help further...
India saw a spike in COVID-19 cases early 2023, and this wave of infection was attributed to XBB sublineages SARS-CoV-2 Omicron variant. The impact significantly shorter with low burden severe or hospitalization as compared previous variants concern. Although combination old new mutations the region XBB.1.16 variant led drastic reduction ability antibodies from prior immunity neutralize virus, additional nonspike suggested possible change its suppress innate immune responses. In study, we...
The frequency and complexity of cyber assaults have risen considerably in recent years, resulting major financial losses reputational harm for both corporations people. Traditional cybersecurity measures, such as firewalls encryption, been insufficient protecting against these threats. Due to a rise data breaches, there is an increased need effective solutions. With its decentralized nature blockchain technology has come out promising option enhancing cybersecurity. This article investigates...
ABSTRACT The Omicron variant of SARS-CoV-2 is capable infecting unvaccinated, vaccinated and previously-infected individuals due to its ability evade neutralization by antibodies. With three sub-lineages emerging in the last four months, there inadequate information on quantitative antibody response generated upon natural infection with whether these antibodies offer cross-protection against other variant. In this study, we characterized growth kinetics Kappa, Delta variants Calu-3 cells....
Abstract The emergence of new variants SARS-CoV-2 necessitates unremitting efforts to discover novel therapeutic mAbs. Here, we report an extremely potent mAb named P4A2 that can neutralize all the circulating concerns (VOCs) with high efficiency, including highly transmissible Omicron. crystal structure Fab:RBD complex revealed residues RBD interact are part ACE2-receptor-binding motif and not mutated in any VOCs. pan coronavirus pseudotyped neutralization assay confirmed is specific for...
Background: We present the data from an open-label study involved in selection of optimum formulation receptor binding domain (RBD)-based protein sub-unit COVID-19 vaccine. Methods: The randomized Phase-1/2 trial followed by a Phase-2 was carried out to assess safety and immunogenicity different vaccine (Corbevax) select for Phase 3 study. Healthy adults without history Covid-19 vaccination or SARS-CoV-2 infection, were enrolled. Findings: Low incidence adverse events reported post Corbevax...
ABSTRACT Most adults in India have received at least one dose of COVID-19 vaccine and also been infected naturally during the pandemic. As immunization individuals continues under this situation where virus has attained endemicity, we assessed whether hybrid immunity is further boosted by a single BBV152, an inactivated SARS-CoV-2 vaccine, and, if these antibodies can neutralize delta omicron variants. We found that natural infection second wave 2021 led to generation neutralizing against...
ABSTRACT Background After establishing safety and immunogenicity of Biological E’s CORBEVAX™ vaccine in adult population (18-80 years) Phase 1-3 studies, is further tested children adolescents this study. Methods This a phase-2/3 prospective, randomised, double-blind, placebo controlled, study evaluating safety, reactogenicity, tolerability either gender between <18 to ≥12 years age Phase-II ≥5 Phase-III with as control. has two sub groups; subgroup-1 subjects subgroup-2 <12 age. In...
Understanding the quality of immune repertoire triggered during natural infection can provide vital clues that form basis for development a humoral response in some individuals capable broadly neutralizing pan-SARS-CoV-2 variants. In present study, we report variations neutralization potential against Omicron variants two novel monoclonal antibodies (MAbs), THSC20.HVTR11 and THSC20.HVTR55, isolated from an unvaccinated convalescent individual represent distinct B cell lineage origins epitope...